NO20081713L - Pyrimidine derivatives and their use as KCNQ potassium channel openers - Google Patents
Pyrimidine derivatives and their use as KCNQ potassium channel openersInfo
- Publication number
- NO20081713L NO20081713L NO20081713A NO20081713A NO20081713L NO 20081713 L NO20081713 L NO 20081713L NO 20081713 A NO20081713 A NO 20081713A NO 20081713 A NO20081713 A NO 20081713A NO 20081713 L NO20081713 L NO 20081713L
- Authority
- NO
- Norway
- Prior art keywords
- pyrimidine derivatives
- potassium channel
- channel openers
- kcnq potassium
- openers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Den foreliggende oppfinnelse vedrører pyrimidinderivater med den generelle formelen I eller salter av disse og bruken av dem som åpnere av KNCQ familiens kaliumionekanaler, spesielt til behandling av epilepsi.The present invention relates to pyrimidine derivatives of the general formula I or their salts and their use as openers of the KNCQ family's potassium ion channels, in particular for the treatment of epilepsy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200501262 | 2005-09-09 | ||
PCT/DK2006/050039 WO2007065449A1 (en) | 2005-09-09 | 2006-09-07 | Pyrimidine derivatives and their use as kcnq potassium channels openers |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20081713L true NO20081713L (en) | 2008-06-04 |
Family
ID=37199174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20081713A NO20081713L (en) | 2005-09-09 | 2008-04-09 | Pyrimidine derivatives and their use as KCNQ potassium channel openers |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1937653A1 (en) |
JP (1) | JP2009507052A (en) |
KR (1) | KR20080043314A (en) |
CN (1) | CN101258133A (en) |
AR (1) | AR055420A1 (en) |
AU (1) | AU2006322461A1 (en) |
BR (1) | BRPI0615631A2 (en) |
CA (1) | CA2621854A1 (en) |
EA (1) | EA200800780A1 (en) |
IL (1) | IL189545A0 (en) |
MX (1) | MX2008002294A (en) |
NO (1) | NO20081713L (en) |
UA (1) | UA93387C2 (en) |
WO (1) | WO2007065449A1 (en) |
ZA (1) | ZA200802174B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2694887A1 (en) * | 2007-08-01 | 2009-02-05 | Henriette Husum Bak-Jensen | Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted |
US7786146B2 (en) * | 2007-08-13 | 2010-08-31 | Valeant Pharmaceuticals International | Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators |
WO2010097379A1 (en) * | 2009-02-24 | 2010-09-02 | Neurosearch A/S | Substituted pyrimidin derivatives and their medical use |
EP2590961A1 (en) * | 2010-07-08 | 2013-05-15 | Pfizer Inc | Piperidinyl pyrimidine amides as kv7 potassium channel openers |
MX367623B (en) * | 2010-10-20 | 2019-08-29 | Gruenenthal Gmbh | Substituted 6-amino-nicotinamides as kcnq2/3 modulators. |
CN103508960B (en) * | 2012-06-29 | 2017-12-12 | 江苏先声药业有限公司 | Benzheterocyclic derivatives |
CN103508943B (en) * | 2012-06-29 | 2017-06-09 | 江苏先声药业有限公司 | As the compound of potassium channel modulating agents |
EP3210969B1 (en) | 2014-10-24 | 2021-04-28 | ONO Pharmaceutical Co., Ltd. | Kcnq2-5 channel activator |
US20220280455A1 (en) * | 2019-08-02 | 2022-09-08 | H. Lundbeck A/S | Alcohol derivatives as kv7 potassium channel openers for use in epilepsy or seizures |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002066036A1 (en) * | 2001-02-20 | 2002-08-29 | Bristol-Myers Squibb Company | 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators |
WO2003068769A1 (en) * | 2002-02-12 | 2003-08-21 | Pfizer Inc. | Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh) |
US20080261918A1 (en) * | 2004-12-17 | 2008-10-23 | Graham Andrew Showell | Silicon Compounds and Their Use |
-
2006
- 2006-09-07 WO PCT/DK2006/050039 patent/WO2007065449A1/en active Application Filing
- 2006-09-07 UA UAA200803570A patent/UA93387C2/en unknown
- 2006-09-07 CN CNA2006800327125A patent/CN101258133A/en active Pending
- 2006-09-07 MX MX2008002294A patent/MX2008002294A/en active IP Right Grant
- 2006-09-07 AU AU2006322461A patent/AU2006322461A1/en not_active Abandoned
- 2006-09-07 CA CA002621854A patent/CA2621854A1/en not_active Abandoned
- 2006-09-07 BR BRPI0615631-2A patent/BRPI0615631A2/en not_active IP Right Cessation
- 2006-09-07 JP JP2008529473A patent/JP2009507052A/en not_active Withdrawn
- 2006-09-07 EA EA200800780A patent/EA200800780A1/en unknown
- 2006-09-07 ZA ZA200802174A patent/ZA200802174B/en unknown
- 2006-09-07 EP EP06846967A patent/EP1937653A1/en not_active Withdrawn
- 2006-09-07 KR KR1020087004306A patent/KR20080043314A/en not_active Application Discontinuation
- 2006-09-08 AR ARP060103924A patent/AR055420A1/en not_active Application Discontinuation
-
2008
- 2008-02-14 IL IL189545A patent/IL189545A0/en unknown
- 2008-04-09 NO NO20081713A patent/NO20081713L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2009507052A (en) | 2009-02-19 |
UA93387C2 (en) | 2011-02-10 |
BRPI0615631A2 (en) | 2011-05-24 |
AU2006322461A1 (en) | 2007-06-14 |
KR20080043314A (en) | 2008-05-16 |
ZA200802174B (en) | 2009-10-28 |
CN101258133A (en) | 2008-09-03 |
CA2621854A1 (en) | 2007-06-14 |
IL189545A0 (en) | 2008-06-05 |
AR055420A1 (en) | 2007-08-22 |
MX2008002294A (en) | 2008-03-14 |
EP1937653A1 (en) | 2008-07-02 |
EA200800780A1 (en) | 2008-06-30 |
WO2007065449A1 (en) | 2007-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20081713L (en) | Pyrimidine derivatives and their use as KCNQ potassium channel openers | |
NO20071843L (en) | Substituted aniline derivatives | |
NO20080675L (en) | P38-Map kinase inhibitors and methods for their use | |
NO20074959L (en) | Substituted pyridine derivatives | |
SG164368A1 (en) | Treatment of cancer | |
NO20091509L (en) | Substituted tetrahydropyrrolopyrazine compounds with affinity KCNQ2 / 3 K + channel and its use in drugs | |
WO2007027238A3 (en) | Jak kinase inhibitors and their uses | |
NO20064976L (en) | Azanidols useful as inhibitors of rock and other protein kinases | |
MX2009006195A (en) | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use. | |
MX2009011211A (en) | 7-substituted indole mcl-1 inhibitors. | |
MX2009011210A (en) | 7-nonsubstituted indole mcl-1 inhibitors. | |
SG170828A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
GEP20094785B (en) | Pyrrolopyrazoles, potent kinase inhibitors | |
NO20071549L (en) | New benzofused heteroalrylsulfamide derivatives, useful as anticonvulsants | |
NO20066055L (en) | pyridine derivatives | |
NO20076054L (en) | Imidiazo and triazolopyridines as inhibitors of 11-beta-hydroxysteroid dehydrogenase type I | |
NO20081454L (en) | Met kinase inhibitors | |
TN2009000128A1 (en) | Dihydropyridine derivatives useful as protein kinase inhibitors | |
WO2005110994A3 (en) | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | |
WO2007092622A3 (en) | Compositions and methods for treating bone | |
NO20062020L (en) | 1-Amino-2-Oxy-Substituted Tetrahydronaphthalene Derivatives, Methods of Preparation thereof, and Their Use as Antiflogistics | |
NO20090157L (en) | Ten pyrimidines useful as modulators of ion channels | |
SI1937669T1 (en) | Novel benzopyran derivatives as potassium channel openers | |
NO20054371L (en) | Somatostatin-dopamine chimeric analogs | |
NO20082096L (en) | Azaindole-2-karboksamidderivativer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104 |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |